Safety and Effectiveness of Cyclosporin in the Management of COVID19 ARDS Patients in Alexandria University Hospital

Pulmonary Fibrosis Clinical Trial

Official title: Safety and Therapeutic Efficacy of Cyclosporine Plus Standard of Care Treatment on ARDS in COVID -19 Patients at Alexandria University Hospitals in 2021: a Comparative Study

Status Completed

Clinical Trial Summary

The study to evaluate the effect of cyclosporine ( IL2 inhibitor and antiviral) verse standard care treatment on decrease ADRS, hyper inflammation, hypercytokinemia, and the mortality rate

Clinical Trial Description

To test the efficacy of IL-2 inhibitors (Cyclosporine) compared to the Standard of care according to hospital protocol on COVID-19 patients concerning the clinical outcome (cytokines level, clinical improvement, and PCR of SARS-CoV-2 through the study period).

AIM:

The slow progression of the disease, improving survival among COVID-19 patients, and Standard assessment of patient improvement.

• Standard assessment of patient improvement:

• PCR-SARS-CoV-2 negative

• No fever

• No cytopenia (Hb ≥90 g/L, ANC ≥0.5x109/L, platelets ≥100x109/L) •

• No hyperferritinemia ≥500 μg/L

• (Decrease of IL2) ;

Related Conditions & MeSH terms

• Acute Lung Injury
• COVID-19
• Cytokine Release Syndrome
• Pulmonary Fibrosis
• Respiratory Distress Syndrome
• Respiratory Distress Syndrome, Newborn
• Syndrome

• NCT number: NCT04979884
• Study type: Interventional
• Source: Alexandria University
• Status: Completed
• Phase: Phase 3
• Start date: January 3, 2022
• Completion date: December 9, 2022